COVID-19 mRNA vaccines update 7

As new data emerges, this is our first video about vaccination consequences on a molecular level. Three different publications are discussed, two of which indicate that different COVID-19 vaccines could result in spike protein being released into the blood, and a third paper indicating that the binding of spike proteins to human receptors affects signaling within the cell. Also discussed is what the potential consequences of these events could be, and why this might be a cause of concern but ultimately why it is not necessarily an immediate need for worry.

**************************************************************
Dr. Raszek Credentials: https://merogenomics.ca/en/about/
_____________________________________________________________

Please stay in touch with us on other social media channels:

Twitter: https://twitter.com/merogenomics
Facebook: https://www.facebook.com/merogenomics/
LinkedIn: https://www.linkedin.com/company/merogenomics
Blog: https://merogenomics.ca/blog/
Newsletter Signup: http://eepurl.com/hesNGf
Instagram: https://www.instagram.com/merogenomics/
_____________________________________________________
0:00 intro

1:35 Astra Zeneca -news from Germany on this DNA vaccine

4:00 Soluble spike proteins in the bloodstream and clots

5:24 Differences of genetic code vaccines

6:10 Moderna has soluble spike proteins in bloodstream

8:00 Spike protein as a receptor messenger

9:35 Spike protein and side-effects -Pulmonary Arterial Hypertension as side effect and past example

12:20 Alleviating concerns: Good news! Moderna findings very small amounts of spike protein and transient. Immune system working means increased antibodies with decreased killer cellular immunity

16:25 Risks of vaccinated vs. non vaccinated

17:30 More good news: Moderna small study safe in children

*Correction* At about 10:45 - Not 50% of people who took the medication died! It is 50% of the PAH patients who got PAH from taking Aminorex or 0.2x 50% =0.1%

The discussed paper states: "Approximately 0.2% of people who took this drug developed PAH. An epidemic was observed two years after the introduction of aminorex, and half of the patients died 10 years after the epidemic." (https://www.mdpi.com/2076-393X/9/1/36/htm)